Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy (TelOG)

There are no recommendations and few studies on the monitoring of fragile patients in the oncological treatment, both on the organizational arrangements on its interest in the prevention of functional deterioration of the patient and adaptation of the potential cancer treatment.

The oncogériatrique evaluation being time-consuming, requiring the movement of these more or less frail elderly patients, it seems difficult to envisage repeated and systematic standardized geriatric assessments during cancer treatment. Geriatric fragility can be detected by telephone. Craven et al. has already assessed the telephone follow-up by a nurse in patients treated for cancer, but with the aim to detect toxicities of cancer treatment, patients are not very old (mean age 64.8 years).

External evaluation by the nurse coordinator of UCOG (Coordination Unit in geriatric oncology) not knowing the patients included avoids bias of subjectivity in the interrogation.

However the telephone monitoring, with the aim to evaluate the evolution of geriatric frailty, has not been specifically studied in the elderly population treated for cancer, while taking oncology load.

The investigators wish to study the feasibility and validity of telephone follow-up which could eventually be used routinely to identify patients requiring further medical consultation oncogériatrique.

Study Overview

• Status: Completed
• Conditions: Cancer; Hematologic Malignancy
• Intervention / Treatment: Other: Nurse telephone contact

• Study Type: Interventional
• Enrollment (Actual): 131
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Bayeux, France
    • Centre hospitalier
  • Caen, France, 14033
    • CHU
  • Caen, France, 14400
    • Centre François Baclesse
  • Dieppe, France
    • Centre hospitalier
  • Le Havre, France
    • Centre Hospitalier du Havre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 70 years and older (Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients 70 years and older with cancer or hematologic malignancies;
• Faced benefit from cancer treatment (systemic treatment, curative radiotherapy) in one of the clinical sites;
• Addressed in onco-gériatric consultation in the usual routine care sector;
• Mastery of the French language;
• Patient affiliated to the social security system;
• Patient has given its written consent.

Exclusion Criteria:

• Life expectancy <3 months
• Inability to communicate by telephone (deafness, speech disorder, ..)
• Inability collection of written consent
• Group 4 SiO (International Society of Geriatric Oncology), Performance status (PS) 4
• initial MMSE (Mini-Mental State Examination) <18/30
• oncological treatment envisaged: analgesic radiotherapy or exclusive decompressive, brain radiation therapy in toto
• Patient under guardianship

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Nurse telephone contact; 3 days of consultation, telephone follow-up of the patient by the nurse coordinator of the Geriatric Oncology Unit to validate	Other: Nurse telephone contact; Nurse will contact patient 3 days before consultation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Memory on the Mini Mental Scale	3 months after inclusion
Falls on the number of falls	3 months after inclusion
Pain on the EVS (verbal scale) scale	3 months after inclusion
Autonomy on the ADL (activities of daily living) score	3 months after inclusion
Pain on the EN (numericale scale) scale	3 months after inclusion
Autonomy on the IADL (The Lawton Instrumental Activities of Daily Living Scale ) score	3 months after inclusion

Collaborators and Investigators

• Sponsor: Centre Francois Baclesse
• Investigators: Principal Investigator: Bérengère Beauplet, MD, University Hospital, Caen

Study record dates

Study Major Dates

• Study Start: February 1, 2015
• Primary Completion (Actual): February 16, 2018
• Study Completion (Actual): May 14, 2018

Study Registration Dates

• First Submitted: September 17, 2015
• First Submitted That Met QC Criteria: October 20, 2015
• First Posted (Estimate): October 21, 2015

Study Record Updates

• Last Update Posted (Actual): January 16, 2019
• Last Update Submitted That Met QC Criteria: January 15, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Keywords: cancer; geriatric
• Additional Relevant MeSH Terms: Neoplasms by Site; Hematologic Diseases; Neoplasms; Hematologic Neoplasms
• Other Study ID Numbers: TelOG